Simultaneous administration of EZH2 and BET inhibitors inhibits proliferation and clonogenic ability of metastatic prostate cancer cells

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA A Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263–282.
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182–5191.
   PubMed Web of Science ®Google Scholar
• Marchetti A, Rosellini M, Nuvola G, Tassinari E, Mollica V, Rizzo A, Santoni M, Cimadamore A, Farolfi A, Montironi R, et al. PARP inhibitors and radiometabolic approaches in metastatic castration-resistant prostate cancer: what’s now, what’s new, and what’s coming? Cancers. 2022;14(4):907.
   PubMed Web of Science ®Google Scholar
• Kumaraswamy A, Welker Leng KR, Westbrook TC, Yates JA, Zhao SG, Evans CP, Feng FY, Morgan TM, Alumkal JJ. Recent advances in epigenetic biomarkers and epigenetic targeting in prostate cancer. Eur Urol. 2021;80(1):71–81.
   PubMed Web of Science ®Google Scholar
• Bonacini M, Coletta M, Ramazzina I, Naponelli V, Modernelli A, Davalli P, Bettuzzi S, Rizzi F. Distinct promoters, subjected to epigenetic regulation, drive the expression of two clusterin mRNAs in prostate cancer cells. Biochim Biophys Acta. 2015;1849(1):44–54.
   PubMed Web of Science ®Google Scholar
• Baumgart SJ, Haendler B. Exploiting epigenetic alterations in prostate cancer. IJMS. 2017;18(5):1017.
   Google Scholar
• Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403(6765):41–45.
   PubMed Web of Science ®Google Scholar
• Piunti A, Shilatifard A. The roles of Polycomb repressive complexes in mammalian development and cancer. Nat Rev Mol Cell Biol. 2021;22(5):326–345.
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RGAB, Otte AP, et al. The Polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624–629.
   PubMed Web of Science ®Google Scholar
• Saramäki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T. The gene for Polycomb group protein enhancer of Zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer. 2006;45(7):639–645.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang GG. No easy way out for EZH2: its pleiotropic, noncanonical effects on gene regulation and cellular function. IJMS. 2020;21(24):9501.
   Google Scholar
• Park SH, Fong KW, Mong E, Martin MC, Schiltz GE, Yu J. Going beyond Polycomb: EZH2 functions in prostate cancer. Oncogene. 2021;40(39):5788–5798.
   PubMed Web of Science ®Google Scholar
• Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012;338(6113):1465–1469.
   PubMed Web of Science ®Google Scholar
• Wee ZN, Li Z, Lee PL, Lee ST, Lim YP, Yu Q. EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer. Cell Rep. 2014;8(1):204–216.
   PubMed Web of Science ®Google Scholar
• Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature. 2012;488(7411):404–408.
   PubMed Web of Science ®Google Scholar
• Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. 2016;22(2):128–134.
   PubMed Web of Science ®Google Scholar
• Karanikolas BD, Figueiredo ML, Wu L. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate. 2010;70(6):675–688.
   PubMed Web of Science ®Google Scholar
• Wu C, Jin X, Yang J, Yang Y, He Y, Ding L, Pan Y, Chen S, Jiang J, Huang H, et al. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer. Oncotarget. 2016;7(3):3440–3452.
   PubMedGoogle Scholar
• Bai Y, Zhang Z, Cheng L, Wang R, Chen X, Kong Y, Feng F, Ahmad N, Li L, Liu X. Inhibition of enhancer of Zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer. J Biol Chem. 2019;294(25):9911–9923.
   PubMed Web of Science ®Google Scholar
• Huang X, Yan J, Zhang M, Wang Y, Chen Y, Fu X, Wei R, Zheng XL, Liu Z, Zhang X, et al. Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors. Cell. 2018;175(1):186.e19–199.e19.
   Web of Science ®Google Scholar
• Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014;510(7504):278–282.
   PubMed Web of Science ®Google Scholar
• Urbanucci A, Mills IG. Bromodomain-containing proteins in prostate cancer. Mol Cell Endocrinol. 2018;462(Pt A):31–40.
   PubMedGoogle Scholar
• Taniguchi Y. The bromodomain and extra-terminal domain (BET) family: functional anatomy of BET paralogous proteins. IJMS. 2016;17(11):1849.
   Google Scholar
• Welti J, Sharp A, Yuan W, Dolling D, Nava Rodrigues D, Figueiredo I, Gil V, Neeb A, Clarke M, Seed G, et al. Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC). Clin Cancer Res. 2018;24(13):3149–3162.
   PubMed Web of Science ®Google Scholar
• Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L, Sims RJ. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A. 2011;108(40):16669–16674.
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067–1073.
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014;13(5):337–356.
   PubMed Web of Science ®Google Scholar
• Gao L, Schwartzman J, Gibbs A, Lisac R, Kleinschmidt R, Wilmot B, Bottomly D, Coleman I, Nelson P, McWeeney S, et al. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS One. 2013;8(5):e63563.
   PubMed Web of Science ®Google Scholar
• Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018;3:5.
   PubMed Web of Science ®Google Scholar
• Carabet LA, Rennie PS, Cherkasov A. Therapeutic inhibition of Myc in cancer. Structural bases and computer-aided drug discovery approaches. IJMS. 2018;20(1):120.
   Google Scholar
• Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H, Sun L, Zhang Y, Chen Y, Li R, et al. Integration of estrogen and Wnt signaling circuits by the Polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol. 2007;27(14):5105–5119.
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904–917.
   PubMed Web of Science ®Google Scholar
• Labrecque MP, Alumkal JJ, Coleman IM, Nelson PS, Morrissey C. The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches. Endocr Relat Cancer. 2021;28(8):T51–T66.
   PubMed Web of Science ®Google Scholar
• Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines–part 1. J Urol. 2005;173(2):342–359.
   PubMedGoogle Scholar
• Coleman DJ, Gao L, Schwartzman J, Korkola JE, Sampson D, Derrick DS, Urrutia J, Balter A, Burchard J, King CJ, et al. Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer. Sci Rep. 2019;9(1):3823.
   PubMedGoogle Scholar
• Jin M, Duan J, Liu W, Ji J, Liu B, Zhang M. Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells. Cancer Cell Int. 2021;21(1):191.
   PubMed Web of Science ®Google Scholar
• Fallara G, Robesti D, Nocera L, Raggi D, Marandino L, Belladelli F, Montorsi F, Malavaud B, Ploussard G, Necchi A, et al. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis. Cancer Treat Rev. 2022;110:102441.
   PubMed Web of Science ®Google Scholar
• Okasho K, Ogawa O, Akamatsu S. Narrative review of challenges in the management of advanced neuroendocrine prostate cancer. Transl Androl Urol. 2021;10(10):3953–3962.
   PubMed Web of Science ®Google Scholar
• Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32(4):474.e6–489.e6.
   Web of Science ®Google Scholar
• Dockerill M, Gregson C, O' Donovan DH. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020). Expert Opin Ther Pat. 2021;31(2):119–135.
   PubMed Web of Science ®Google Scholar
• Markowski MC, De Marzo AM, Antonarakis ES. BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations. Expert Opin Investig Drugs. 2017;26(12):1391–1397.
   PubMed Web of Science ®Google Scholar
• Liao Y, Chen CH, Xiao T, de la Peña Avalos B, Dray EV, Cai C, Gao S, Shah N, Zhang Z, Feit A, et al. Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. Proc Natl Acad Sci U S A. 2022;119(3):e2105898119.
   PubMed Web of Science ®Google Scholar
• La Rosa FA, Pierce JW, Sonenshein GE. Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel fam-ily of transcription factors. Mol Cell Biol. 1994;14(2):1039–1044.
   PubMed Web of Science ®Google Scholar
• Dong J, Li J, Li Y, Ma Z, Yu Y, Wang C-Y. Transcriptional super-enhancers control cancer stemness and metastasis genes in squamous cell carcinoma. Nat Commun. 2021;12(1):3974.
   PubMed Web of Science ®Google Scholar
• Coleman DJ, Gao L, King CJ, Schwartzman J, Urrutia J, Sehrawat A, Tayou J, Balter A, Burchard J, Chiotti KE, et al. BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer. Oncogene. 2019;38(28):5658–5669.
   PubMed Web of Science ®Google Scholar
• Zou Z, Huang B, Wu X, Zhang H, Qi J, Bradner J, Nair S, Chen LF. Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA. Oncogene. 2014;33(18):2395–2404.
   PubMed Web of Science ®Google Scholar
• Bonacini M, Negri A, Davalli P, Naponelli V, Ramazzina I, Lenzi C, Bettuzzi S, Rizzi F. Clusterin silencing in prostate cancer induces matrix metalloproteinases by an nf-κb-dependent mechanism. J Oncol. 2019;2019:4081624.
   PubMed Web of Science ®Google Scholar
• Marozzi M, Parnigoni A, Negri A, Viola M, Vigetti D, Passi A, Karousou E, Rizzi F. Inflammation, extracellular matrix re-modeling, and proteostasis in tumor microenvironment. IJMS. 2021;22(15):8102.
   Google Scholar
• Yang GJ, Song YQ, Wang W, Han QB, Ma DL, Leung CH. An optimized BRD4 inhibitor effectively eliminates NF-κB-driven triple-negative breast cancer cells. Bioorg Chem. 2021;114:105158.
   PubMed Web of Science ®Google Scholar
• Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 2002;1(8):639–649.
   PubMed Web of Science ®Google Scholar
• Qiu X, Boufaied N, Hallal T, Feit A, de Polo A, Luoma AM, Alahmadi W, Larocque J, Zadra G, Xie Y, et al. MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nat Commun. 2022;13(1):2559.
   PubMed Web of Science ®Google Scholar